Literature DB >> 7576424

Profiles of neuromuscular diseases. Duchenne muscular dystrophy.

C M McDonald1, R T Abresch, G T Carter, W M Fowler, E R Johnson, D D Kilmer, B J Sigford.   

Abstract

One hundred and sixty-two patients with Duchenne muscular dystrophy (DMD) were followed over a 10-yr period to provide a profile of impairment and disability. The median height and weight of DMD boys were normally distributed before ages 9-10, but during the second decade height was markedly reduced, and weight was no longer normally distributed. Younger boys gained more weight than normals, whereas older individuals actually showed weight loss. Manual muscle test (MMT) measurements showed loss of strength in a fairly linear fashion from ages 5-13 yr, -0.25 MMT units per year. Upper extremity muscles were stronger than lower extremity muscles, proximal muscle groups were weaker than distal muscle groups, and extensor muscles were weaker than flexor muscles. There was no side dominance. There was a change in the rate of strength loss at 14-15 yr, and the decline slowed to only -0.06 MMT units per year. Although MMT and quantitative strength measurement profiles were similar, the latter were far more sensitive. In general, by the time strength declined to MMT grade 4, isometrically measured strength was 40-50% of normal control values. Joint contractures were rare before age 9, increased in frequency and severity with age, and were present in most individuals older than 13. Lower extremity contractures were strongly related to onset of wheelchair reliance, but there was no association between muscle imbalance around a joint. The prevalence of scoliosis increased between ages 11 and 16, with about 50% of the boys acquiring scoliosis between ages 12 and 15, corresponding to the onset of the adolescent growth spurt. Wheelchair reliance and scoliosis were both age-related. Percent predicted forced vital capacity declined at different yearly rates: ages 7-10, -0.3%; ages 10-20, -8.5%; after age 20, -6.2%. There was a direct relationship between percent predicted FVC and MMT scores. Decreased airway pressures, especially maximal expiratory pressure, appeared earlier than reductions in FVC but followed the same pattern. Thirty percent of the DMD boys had a history of respiratory complications, and the frequency increased with age. Spine deformity did not have a significant additive effect on the age-related decrement in pulmonary function. There was a high occurrence (79%) of abnormal electrocardiograms with age-related progression of some abnormalities, but only 30% of the patients had a history of cardiovascular complications. Functional level grades and timed motor performance measurements had a nonlinear relationship with strength and age.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7576424     DOI: 10.1097/00002060-199509001-00003

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  104 in total

1.  Patterns of decline in upper limb function of boys and men with DMD: an international survey.

Authors:  Mariska M H P Janssen; Arjen Bergsma; Alexander C H Geurts; Imelda J M de Groot
Journal:  J Neurol       Date:  2014-04-01       Impact factor: 4.849

Review 2.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

3.  Two-Year Longitudinal Changes in Lower Limb Strength and Its Relation to Loss in Function in a Large Cohort of Patients With Duchenne Muscular Dystrophy.

Authors:  Abhinandan Batra; Ann Harrington; Donovan J Lott; Rebecca Willcocks; Claudia R Senesac; William McGehee; Dandan Xu; Sunita Mathur; Michael J Daniels; William D Rooney; Sean C Forbes; William Triplett; Jasjit K Deol; Ishu Arpan; Roxanne Bendixen; Richard Finkel; Erika Finanger; Gihan Tennekoon; Barry Byrne; Barry Russman; H Lee Sweeney; Glenn Walter; Krista Vandenborne
Journal:  Am J Phys Med Rehabil       Date:  2018-10       Impact factor: 2.159

4.  The natural history of cardiac and pulmonary function decline in patients with duchenne muscular dystrophy.

Authors:  Rolando Roberto; Anto Fritz; Yolanda Hagar; Braden Boice; Andrew Skalsky; Hosun Hwang; Laurel Beckett; Craig McDonald; Munish Gupta
Journal:  Spine (Phila Pa 1976)       Date:  2011-07-01       Impact factor: 3.468

5.  Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

Authors:  D M Escolar; L P Hache; P R Clemens; A Cnaan; C M McDonald; V Viswanathan; A J Kornberg; T E Bertorini; Y Nevo; T Lotze; A Pestronk; M M Ryan; E Monasterio; J W Day; A Zimmerman; A Arrieta; E Henricson; J Mayhew; J Florence; F Hu; A M Connolly
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

Review 6.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

7.  Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials.

Authors:  Jacob J Gissy; Teresa Johnson; Deborah J Fox; Anil Kumar; Emma Ciafaloni; Anthonie J van Essen; Holly L Peay; Ann Martin; Ann Lucas; Richard S Finkel
Journal:  Neuromuscul Disord       Date:  2017-07-21       Impact factor: 4.296

8.  Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  David R Weber; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; Leanne M Ward
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

Review 9.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

10.  Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study.

Authors:  Merel Jansen; Imelda Jm de Groot; Nens van Alfen; Alexander Ch Geurts
Journal:  BMC Pediatr       Date:  2010-08-06       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.